(Q35206946)

7 August 2017

1 reference

title

Beyond Herceptin and Gleevec (English)

1 reference

7 August 2017

Oliver M Fischer

1

1 reference

7 August 2017

Sylvia Streit

series ordinal

2

1 reference

7 August 2017

Stefan Hart

series ordinal

3

1 reference

7 August 2017

Axel Ullrich

series ordinal

4

1 reference

7 August 2017

language of work or name

1 reference

1 August 2003

1 reference

Current Opinion in Chemical Biology

7 August 2017

1 reference

7 August 2017

7

1 reference

7 August 2017

490-495

1 reference

7 August 2017

4

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 August 2017

1 reference

7 January 2021

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Specificity within the EGF family/ErbB receptor family signaling network

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

The epidermal growth factor receptor as a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Clinical translation of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Platelet-derived growth factor receptors: a therapeutic target in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Involvement of platelet-derived growth factor in disease: development of specific antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

New insights into the interaction of Ras with the plasma membrane

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Agents targeting ras signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Influence of unrecognized molecular heterogeneity on randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2803%2900082-6

7 January 2021

10.1016/S1367-5931(03)00082-6

Identifiers

DOI

1 reference

7 August 2017

1 reference